Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
Andrew Alexis
(1)
,
Marjolein de Bruin-Weller
(2)
,
Stephan Weidinger
(3)
,
Weily Soong
(4)
,
Sebastien Barbarot
(5)
,
Ileana Ionita
(6)
,
Fan Zhang
(7)
,
Hernan Valdez
(6)
,
Claire Clibborn
(6)
,
Natalie Yin
(6)
1
Weill Medical College of Cornell University [New York]
2 UMCU - University Medical Center [Utrecht]
3 UKSH - University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein
4 Clinical Research Center of Alabama
5 PhAN - Physiopathologie des Adaptations Nutritionnelles
6 Pfizer Ltd
7 School of Aeronautics and Astronautics(Shenzhen) Sun Yat-sen University, China
2 UMCU - University Medical Center [Utrecht]
3 UKSH - University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein
4 Clinical Research Center of Alabama
5 PhAN - Physiopathologie des Adaptations Nutritionnelles
6 Pfizer Ltd
7 School of Aeronautics and Astronautics(Shenzhen) Sun Yat-sen University, China